-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer (PCa) is one of the most common malignancies among men worldwide.
despite a 5-year survival rate of nearly 100% in patients with local PCa, metastatic prostate cancer remains incurable.
, there is an urgent need for markers to detect the initial stage of monitoring tumor metastasis, the likelihood of tumor recurrence, and the preferred site for predicting metastasis in order to personalize treatment of patients.
previous studies have shown that intersessional transformation (EMT) and plasticity are associated with the transfer of PCa.
addition, EGFR (epidermosphel growth factor subject) has also been shown to play a vital role in the development of prostate cancer.
there is now evidence that EGFR expression levels are associated with the re-emergence of prostate-specific antigens (PSA), the high risk of bone metastasis, and the malignancy of tumors.
, however, the complex relationship between the expression of EGFR and the characteristics of PCa and PCa transfer needs further study.
EGFR over-expression in primary tumors tracked the over-expression status of EGFR in metastasis (EGFRover) in metastasis samples of 1,039 primary tumors, 39 circulating tumor cells in high-risk patients with Damico, and 21 cases of de-resistance PCa.
researchers detected that EGF was over-expressed in 14 percent of primary tumor samples, corresponding to a shorter, non-transferable lifetime, which is a separate indicator of poor overall survival.
further studies of EGFR expression in cancer metastasis have found that EGFR over-expression status is associated with pre- and pre-metastasis esophageal and rich collagen fiber content of tumor cells.
all circulating tumor cells (detected in 13% of cases) tested positive for EGFR, a result independent of their EMT esoploid.
EGFRover was more common in desirable resistant osteosarcoma (29 percent of patients).
study, the over-expression of EGFR is a stable, EMT-independent marker of prostate cancer's metastasis to the bone.
.
